433 related articles for article (PubMed ID: 38287107)
1. Translating p53-based therapies for cancer into the clinic.
Peuget S; Zhou X; Selivanova G
Nat Rev Cancer; 2024 Mar; 24(3):192-215. PubMed ID: 38287107
[TBL] [Abstract][Full Text] [Related]
2. Targeting p53 for the treatment of cancer.
Duffy MJ; Synnott NC; O'Grady S; Crown J
Semin Cancer Biol; 2022 Feb; 79():58-67. PubMed ID: 32741700
[TBL] [Abstract][Full Text] [Related]
3. p53 as a target for the treatment of cancer.
Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
[TBL] [Abstract][Full Text] [Related]
4. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis.
Di Cintio A; Di Gennaro E; Budillon A
Recent Pat Anticancer Drug Discov; 2010 Jan; 5(1):1-13. PubMed ID: 19663772
[TBL] [Abstract][Full Text] [Related]
5. MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.
Tisato V; Voltan R; Gonelli A; Secchiero P; Zauli G
J Hematol Oncol; 2017 Jul; 10(1):133. PubMed ID: 28673313
[TBL] [Abstract][Full Text] [Related]
6. Targeting p53-MDM2-MDMX loop for cancer therapy.
Zhang Q; Zeng SX; Lu H
Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p53 inhibitors: progress, challenges and perspectives.
Sanz G; Singh M; Peuget S; Selivanova G
J Mol Cell Biol; 2019 Jul; 11(7):586-599. PubMed ID: 31310659
[TBL] [Abstract][Full Text] [Related]
8. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
9. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
10. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
Meek DW; Hupp TR
Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
[TBL] [Abstract][Full Text] [Related]
11. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
[TBL] [Abstract][Full Text] [Related]
12. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
Vicente ATS; Salvador JAR
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological reactivation of p53 as a strategy to treat cancer.
Zawacka-Pankau J; Selivanova G
J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071
[TBL] [Abstract][Full Text] [Related]
14. Drugging p53 in cancer: one protein, many targets.
Hassin O; Oren M
Nat Rev Drug Discov; 2023 Feb; 22(2):127-144. PubMed ID: 36216888
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
Di J; Zhang Y; Zheng J
Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule inhibitors of MDM2 as new anticancer therapeutics.
Dickens MP; Fitzgerald R; Fischer PM
Semin Cancer Biol; 2010 Feb; 20(1):10-8. PubMed ID: 19897042
[TBL] [Abstract][Full Text] [Related]
17. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L
Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
[TBL] [Abstract][Full Text] [Related]
18. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
Twarda-Clapa A; Krzanik S; Kubica K; Guzik K; Labuzek B; Neochoritis CG; Khoury K; Kowalska K; Czub M; Dubin G; Dömling A; Skalniak L; Holak TA
J Med Chem; 2017 May; 60(10):4234-4244. PubMed ID: 28482147
[TBL] [Abstract][Full Text] [Related]
19. Targeting MDM2-p53 interaction for cancer therapy: are we there yet?
Nag S; Zhang X; Srivenugopal KS; Wang MH; Wang W; Zhang R
Curr Med Chem; 2014; 21(5):553-74. PubMed ID: 24180275
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).
Zak K; Pecak A; Rys B; Wladyka B; Dömling A; Weber L; Holak TA; Dubin G
Expert Opin Ther Pat; 2013 Apr; 23(4):425-48. PubMed ID: 23374098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
